A prospetive study of intravenous andoral
flecainide in right ventricular arrhythmia.
Physicians are advised to be cautious if they co-administer mirabegron with medicinal products that have a narrow therapeutic index and are significantly metabolized by CYP2D6, such as thioridazine, Type 1C antiarrhythmics (e.g.,
flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine) (39).
Narrow therapeutic index drugs: A clinical pharmacological consideration to
flecainide. Eur J Clin Pharmacol 71, 549-567.
Baseline NT-Pro BNP level predicts success of cardioversion of atrial fibrillation with
flecainide. Neth Heart J.
Flecainide, a Vaughan Williams class Ic antiarrhythmic, is approved by the Food and Drug Administration for the prevention of paroxysmal atrial fibrillation/flutter, sustained ventricular tachycardia, paroxysmal supraventricular tachycardia including atrioventricular nodal tachycardia, atrioventricular reentrant tachycardia, and other supraventricular tachycardia in patients without structural heart disease.
> Rhythm control medications, including
flecainide (Tambocor), propafenone (Rythmol), Sotalol (Betapace), amiodarone (Cordarone, Pacerone), and dronedarone (Multaq)
Flecainide is an effective drug in arrhythmias developing under beta blockers.
Historically, maintaining sinus rhythm has meant prescribing antiarrhythmic medications, such as amiodarone (Cordarone[R], Pacerone[R]), dofetilide (Tikosyn[R]), dronedarone (Multaq[R]),
flecainide (Tambocor[R]), propafenone (Rhythmol[R]), and Sotalol (Betapace[R]).
While sotalol administration increases iCEB and causes torsade de Pointes (TdP),
flecainide usage decreases iCEB and causes non-TdP ventricular tachycardia or ventricular fibrillation (10).
Calkins suggested, would be to treat the patient with an antiarrhythmic drug, such as amiodarone or
flecainide, and with cardioversion and see whether this stops the AF and makes the patient feel better.
anti-arrhythmic drugs Enkaid (encainide) and Tambocor (
flecainide) in
An evaluation for the remnant substrate was performed after
flecainide infusion (2 mg/kg for 10 minutes), revealing no significant changes in local amplitude in epicardial RVOT, although coved-type ST elevation in surface ECG was accentuated.